AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Racial Disparities in 1 Year Outcomes Among Patients with Rheumatoid Arthritis and Heart Failure with Reduced Ejection Fraction: A Propensity Matched Retrospective Cohort Analysis

By Gujjari S, Ogieuhi IJ, Okorigba EM et al.

Background: Rheumatoid arthritis (RA) confers a two-fold increased risk of heart failure (HF), with reduced ejection fraction (HFrEF) carrying particularly high morbidity. While prior studies have examined the relationship between RA and HF with preserved ejection fraction (HFpEF), racial disparities in outcomes among patients with concurrent RA and HFrEF remain unclear. We examined whether Black/African American (AA) patients with RA-HFrEF had higher mortality and hospitalization than White patients. Methods: We conducted a retrospective cohort study using the TriNetX US Collaborative Network (2015-2024). Patients aged≥18 with seropositive RA, systolic HF, and most-recent LVEF <41% were identified. Cohorts: Black/AA (n=2,030) and White (n=6,701).Primary exposure: race. Primary outcome: 1-year all-cause mortality. Secondary outcomes: HF hospitalization, all-cause hospitalization, AMI, cerebral infarction, 3-point MACE, HF hospitalization or death. PSM (1:1 nearest-neighbor)balanced 30 covariates: demographics, comorbidities (HTN, T2DM, AFib, ischemic heart disease, COPD, SLE, obesity), socioeconomic proxies, GDMT (beta-blockers, ACEi, ARBs, aldosterone antagonists, statins, SGLT2i, GLP-1 agonists, anticoagulants), and labs (GFR, LDL, BMI, HbA1c, BNP, NT-proBNP, LVEF). Results: PSM yielded 1,929 matched pairs, well-balanced in age (67.9 vs. 67.6 years), sex (73.3% vs. 73.9% female), and all covariates (standardized differences < 0.10). Black/AA patients had lower 1-year all-cause mortality than White patients (14.5% vs. 17.0%; RR 0.854 [95% CI 0.737-0.988]; HR 0.843 [95%CI 0.718-0.988]; p=0.035). No significant differences were found in HF hospitalization, all-cause hospitalization, AMI, cerebral infarction, 3-point MACE, or HF hospitalization or death. Kaplan- Meier analyses showed similar event-free survival for most outcomes, except for improved overall survival in AA patients. Conclusions: To our knowledge, this is the first propensity-matched study of racial disparities in the RA-HFrEF population. Contrary to our hypothesis, Black/African American patients with RA-HFrEF had lower 1-year all-cause mortality than White patients, despite similar rates of HF hospitalization and other cardiovascular outcomes. These findings suggest that mortality disparities seen in broader HF populations may not persist in this RA-HFrEF cohort. Future studies should examine whether differences in DMARD exposure modify inflammation and contribute to the observed mortality difference.

doi.org/10.1161/circ.154.suppl_1.14550Populations

AgingResearch.News